Anzeige
Mehr »
Samstag, 28.06.2025 - Börsentäglich über 12.000 News
Blockbuster-Bohrergebnisse: Gold-Antimon-Fund in Nevada trifft geopolitischen Nerv
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 899376 | ISIN: US5147661046 | Ticker-Symbol: LDE
Tradegate
25.06.25 | 09:34
7,300 Euro
+4,29 % +0,300
1-Jahres-Chart
LIFECORE BIOMEDICAL INC Chart 1 Jahr
5-Tage-Chart
LIFECORE BIOMEDICAL INC 5-Tage-Chart
RealtimeGeldBriefZeit
6,9007,10027.06.
6,8507,15027.06.

Aktuelle News zur LIFECORE BIOMEDICAL Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
18.06.Lifecore Signs 10-Year Manufacturing Deal To Support Novel Ophthalmic Therapy-
17.06.Lifecore Biomedical Enters 10-Year Commercial Manufacturing & Supply Agreement with Existing Customer1
17.06.Lifecore Biomedical signs new 10-year commercial manufacturing and supply agreement2
17.06.Lifecore signs 10-year manufacturing deal with key ophthalmic client1
17.06.Lifecore Biomedical, Inc.: Lifecore Biomedical Signs New 10-Year Commercial Manufacturing and Supply Agreement with Key Existing Customer1
17.06.Lifecore Biomedical Q3 2025 slides: Revenue dip amid ambitious growth strategy1
12.06.Lifecore Receives Full Payment Early For $17 Mln Equipment Sale3
LIFECORE BIOMEDICAL Aktie jetzt für 0€ handeln
12.06.Lifecore Biomedical receives accelerated payment of remaining $10M in proceeds from equipment sale1
12.06.Lifecore erhält vorzeitige Zahlung von 10 Millionen US-Dollar für Anlagenverkauf3
12.06.Lifecore Biomedical, Inc.: Lifecore Biomedical Receives Accelerated Payment of Remaining $10 Million in Proceeds from Prior Equipment Sale106CHASKA, Minn., June 12, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) ("Lifecore"), a fully integrated contract development and manufacturing organization ("CDMO"), today announced...
► Artikel lesen
27.05.Lifecore Biomedical Appoints CCO1
27.05.Lifecore appoints new chief commercial officer to drive growth1
27.05.Lifecore Biomedical, Inc.: Lifecore Biomedical Names Mark DaFonseca Chief Commercial Officer101Mr. DaFonseca Possesses Nearly 30 Years of Broad Drug Development Experience, including More than 15 Years Leading High Performing CDMO Sales Organizations Will Leverage Deep Pharma Services Expertise...
► Artikel lesen
22.05.What Makes Lifecore Biomedical (LFCR) a Beneficiary of the Trade Policies?3
21.05.Lifecore stock gains on Outperform rating by William Blair1
16.04.Lifecore Biomedical, Inc.: Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)89CHASKA, Minn., April 16, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) ("Lifecore") a fully integrated contract development and manufacturing organization ("CDMO"), today announced...
► Artikel lesen
14.04.Lifecore Biomedical Taps Thomas Salus as Chief Legal & Administration Officer1
14.04.Lifecore Biomedical, Inc.: Lifecore Biomedical Appoints Thomas D. Salus as Chief Legal and Administration Officer1
10.04.LIFECORE BIOMEDICAL, INC. \DE\ - 8-K, Current Report1
04.04.Lifecore Biomedical targets 12% revenue CAGR and expanded CDMO pipeline by 20271
Weiter >>
42 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1